BG
INSM icon

Bellevue Group’s Insmed INSM Stock Holding History

Bellevue Group’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.64M Sell
10,034
-3,881
-28% -$597K 0.04% 83
2025
Q4 		$2.42M Sell
13,915
-6,336
-31% -$1.16M 0.05% 91
2025
Q3 		$2.92M Sell
20,251
-61,146
-75% -$7.49M 0.06% 87
2025
Q2 		$8.19M Sell
81,397
-69,153
-46% -$5.29M 0.18% 70
2025
Q1 		$11.5M Sell
150,550
-107,933
-42% -$8.26M 0.26% 70
2024
Q4 		$17.8M Sell
258,483
-266,951
-51% -$19.2M 0.34% 67
2024
Q3 		$38.4M Sell
525,434
-496,266
-49% -$36.6M 0.62% 45
2024
Q2 		$68.5M Sell
1,021,700
-1,120,143
-52% -$43.4M 1.11% 23
2024
Q1 		$58.1M Sell
2,141,843
-149,115
-7% -$4.17M 0.89% 31
2023
Q4 		$71M Sell
2,290,958
-871,777
-28% -$22.6M 1.09% 28
2023
Q3 		$79.9M Sell
3,162,735
-138,176
-4% -$3.16M 1.29% 19
2023
Q2 		$69.6M Buy
3,300,911
+7,809
+0.2% +$148K 0.99% 30
2023
Q1 		$56.1M Buy
3,293,102
+15,895
+0.5% +$309K 0.81% 43
2022
Q4 		$65.5M Buy
3,277,207
+62,503
+2% +$1.21M 0.87% 34
2022
Q3 		$69.2M Sell
3,214,704
-406,858
-11% -$9.75M 0.99% 35
2022
Q2 		$71.4M Buy
3,621,562
+69,786
+2% +$1.46M 1.01% 31
2022
Q1 		$83.5M Buy
3,551,776
+30,915
+0.9% +$718K 0.97% 37
2021
Q4 		$95.9M Buy
3,520,861
+135,216
+4% +$3.87M 0.99% 35
2021
Q3 		$93.2M Buy
3,385,645
+264,744
+8% +$6.95M 0.95% 39
2021
Q2 		$88.8M Buy
3,120,901
+643,735
+26% +$19.1M 0.87% 40
2021
Q1 		$84.4M Buy
2,477,166
+860,166
+53% +$32.9M 0.89% 36
2020
Q4 		$53.8M Buy
1,617,000
+396,831
+33% +$14.5M 0.62% 51
2020
Q3 		$39.2M Sell
1,220,169
-236,005
-16% -$6.78M 0.54% 53
2020
Q2 		$40.1M Sell
1,456,174
-157,296
-10% -$3.73M 0.57% 47
2020
Q1 		$25.9M Buy
1,613,470
+29,910
+2% +$709K 0.5% 52
2019
Q4 		$37.8M Buy
1,583,560
+392,080
+33% +$7.98M 0.6% 43
2019
Q3 		$21M Buy
1,191,480
+571,021
+92% +$11M 0.39% 56
2019
Q2 		$15.9M Sell
620,459
-38,975
-6% -$1.09M 0.27% 64
2019
Q1 		$19.2M Sell
659,434
-149,712
-19% -$3.88M 1.05% 29
2018
Q4 		$10.6M Buy
809,146
+242,845
+43% +$3.87M 0.7% 42
2018
Q3 		$11.5M Buy
566,301
+142,250
+34% +$3.21M 0.73% 46
2018
Q2 		$10M Buy
424,051
+89,562
+27% +$2.31M 0.86% 44
2018
Q1 		$7.53M Buy
+334,489
New +$8.8M 0.75% 50

Other funds holding INSM

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bellevue Group's INSM Position: Q1 2026 in Review

Bellevue Group reduced its Insmed (INSM) stake by 28% in Q1 2026, selling an estimated $597K and leaving 10,034 shares worth $1.64M. The position accounts for 0.04% of the portfolio, ranked #83.

Bellevue Group first reported a position in INSM in Q1 2018 and has held it in 33 quarters since. The position peaked at $95.9M in Q4 2021. 669 funds tracked by Wall St. Rank hold INSM as of Q1 2026.

  • Bellevue Group held 10,034 shares of Insmed worth $1.64M as of Q1 2026.
  • Bellevue Group sold 3,881 Insmed shares in Q1 2026, an estimated $597K.
  • Insmed made up 0.04% of Bellevue Group's portfolio in Q1 2026, its #83 holding.
  • Bellevue Group first reported a position in Insmed in Q1 2018 and has held it in 33 quarters since.
  • Bellevue Group's Insmed position peaked at $95.9M in Q4 2021.
  • 669 funds tracked by Wall St. Rank held Insmed as of Q1 2026.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.